Borderline personality disorder

Lancet

Volumn 364, Issue 9432, 2004, Pages 453-461

  Lieb, Klaus ^a   Zanarini, Mary C ^b   Schmahl, Christian ^c   Linehan, Prof Marsha M ^d   Bohus, Prof Martin ^c  

^a UNIVERSITY OF FREIBURG   (Germany)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; MONOAMINE OXIDASE INHIBITOR; OLANZAPINE; OMEGA 3 FATTY ACID; PHENELZINE; SEROTONIN UPTAKE INHIBITOR; TIOTIXENE; TRANYLCYPROMINE; TRIFLUOPERAZINE; VALPROIC ACID;

AFFECT; AGGRESSION; ANXIETY; AUTOMUTILATION; BEHAVIOR THERAPY; BORDERLINE STATE; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DISEASE COURSE; DRUG EFFICACY; EPIDEMIOLOGICAL DATA; EXTRAPYRAMIDAL SYMPTOM; HEALTH PROGRAM; HEREDITY; HOSPITAL; HUMAN; HUMAN RELATION; IMPULSE CONTROL DISORDER; LANGUAGE; MENTAL HEALTH; NEUROBIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PSYCHODYNAMICS; PSYCHOSOCIAL CARE; PSYCHOTHERAPY; REGULATORY MECHANISM; SELF CONCEPT; SEXUAL ABUSE; SUICIDAL BEHAVIOR; SUICIDE; TARDIVE DYSKINESIA;

EID: 3843130946     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)16770-6     Document Type: Conference Paper

References (126)

1. Torgersen S, Kringlen E, Cramer V. The prevalence of personality disorders in a community sample. Arch Gen Psychiatry. 58:2001;590-596
2. Swartz MS, Blazer D, George L, Winfield I. Estimating the prevalence of borderline personality disorder in the community. J Personal Disord. 4:1990;257-272
3. Widiger TA, Weissman MM. Epidemiology of borderline personality disorder. Hosp Comm Psychiatry. 42:1991;1015-1021
4. Skodol AE, Gunderson JG, McGlashan TH, et al. Functional impairment in patients with schizotypal, borderline, avoidant, or obsessive-compulsive personality disorder. Am J Psychiatry. 159:2002;276-283
5. American Psychiatric Association. Practice guideline for the treatment of patients with borderline personality disorder - introduction. Am J Psychiatry. 158:2001;2
6. Zanarini MC, Frankenburg FR, Khera GS, Bleichmar J. Treatment histories of borderline inpatients. Compr Psychiatry. 42:2001;144-150
7. Bender DS, Dolan RT, Skodol AE, et al. Treatment utilization by patients with personality disorders. Am J Psychiatry. 158:2001;295-302
8. Bernstein DP, Cohen P, Velez CN, Schwab-Stone M, Siever LJ, Shinsato L. Prevalence and stability of the DSM-III-R personality disorders in a community-based survey of adolescents. Am J Psychiatry. 150:1993;1237-1243
9. Zanarini MC, Gunderson JG, Frankenburg FR, Chauncey DL. Discriminating borderline personality disorder from other axis II disorders. Am J Psychiatry. 147:1990;161-167
10. Zanarini MC, Frankenburg FR, DeLuca CJ, Hennen J, Khera GS, Gunderson JG. The pain of being borderline: dysphoric states specific to borderline personality disorder. Harv Rev Psychiatry. 6:1998;201-207
11. Stiglmayr CE, Shapiro DA, Stieglitz RD, Limberger MF, Bohus M. Experience of aversive tension and dissociation in female patients with borderline personality disorder: a controlled study. J Psychiatr Res. 35:2001;111-118
12. Koenigsberg HW, Harvey PD, Mitropoulou V, et al. Characterizing affective instability in borderline personality disorder. Am J Psychiatry. 159:2002;784-788
13. Zanarini MC, Gunderson JG, Frankenburg FR. Cognitive features of borderline personality disorder. Am J Psychiatry. 147:1990;57-63
14. Pope HG Jr, Jonas JM, Hudson JI, Cohen BM, Tohen M. An empirical study of psychosis in borderline personality disorder. Am J Psychiatry. 142:1985;1285-1290
15. Oldham JM, Skodol AE, Kellman HD, et al. Comorbidity of axis I and axis II disorders. Am J Psychiatry. 152:1995;571-758
16. Zanarini MC, Frankenburg FR, Dubo ED, et al. Axis I comorbidity of borderline personality disorder. Am J Psychiatry. 155:1998;1733-1739
17. Zimmerman M, Mattia JI. Axis I diagnostic comorbidity and borderline personality disorder. Compr Psychiatry. 40:1999;245-252
18. McGlashan TH, Grilo CM, Skodol AE, et al. The Collaborative Longitudinal Personality Disorders Study: baseline axis I/II and II/II diagnostic co-occurrence. Acta Psychiatr Scand. 102:2000;256-264
19. Zanarini MC, Frankenburg FR, Dubo ED, et al. Axis II comorbidity of borderline personality disorder. Compr Psychiatry. 39:1998;296-302
20. Zimmerman M. Diagnosing personality disorders: a review of issues and research models. Arch Gen Psychiatry. 51:1994;225-245
21. Skodol AE, Gunderson JG, Pfohl B, Widiger TA, Livesley WJ, Siever LJ. The borderline diagnosis I: psychopathology, comorbidity, and personality structure. Biol Psychiatry. 51:2002;936-950
22. Skodol AE, Siever LJ, Livesley WJ, Gunderson JG, Pfohl B, Widiger TA. The borderline diagnosis II: biology, genetics, and clinical course. Biol Psychiatry. 51:2002;951-963
23. Torgersen S, Lygren S, Per A, et al. A twin study of personality disorders. Compr Psychiatry. 41:2000;416-425
24. Livesley WJ, Jang KL, Vernon PA. Phenotypic and genetic structure of traits delineating personality disorder. Arch Gen Psychiatry. 55:1998;941-948
25. Zanarini MC, Gunderson JG, Marino MF, Schwartz EO, Frankenburg FR. Childhood experiences of borderline patients. Compr Psychiatry. 30:1989;18-25
26. Zanarini MC, Williams AA, Lewis RE, Reich RB. Reported pathological childhood experiences associated with the development of borderline personality disorder. Am J Psychiatry. 154:1997;1101-1106
27. Links PS, Steiner M, Offord DR, Eppel A. Characteristics of borderline personality disorder: a Canadian study. Can J Psychiatry. 33:1988;336-340
28. Ogata SN, Silk KR, Goodrich S, Lohr NE, Westen D, Hill EM. Childhood sexual and physical abuse in adult patients with borderline personality disorder. Am J Psychiatry. 147:1990;1008-1013
29. Paris J, Zweig-Frank H, Guzder J. Psychological risk factors for borderline personality disorder in female patients. Compr Psychiatry. 35:1994;301-305
30. Paris J, Zweig-Frank H, Guzder J. Risk factors for borderline personality in male outpatients. J Nerv Ment Dis. 182:1994;375-380
31. Shearer SL, Peters CP, Quaytman MS, Ogden RL. Frequency and correlates of childhood sexual and physical abuse histories in adult female borderline inpatients. Am J Psychiatry. 147:1990;214-216
32. Westen D, Ludolph P, Misle B, Ruffins S, Block J. Physical and sexual abuse in adolescent girls with borderline personality disorder. Am J Orthopsychiatry. 60:1990;55-66
33. Herman JL, Perry JC, van der Kolk BA. Childhood trauma in borderline personality disorder. Am J Psychiatry. 146:1989;490-495
34. Zanarini MC, Yong L, Frankenburg FR, et al. Severity of reported childhood sexual abuse and its relationship to severity of borderline psychopathology and psychosocial impairment among borderline inpatients. J Nerv Ment Dis. 190:2002;381-387
35. Silk KR, Lee S, Hill EM, Lohr NE. Borderline personality disorder symptoms and severity of sexual abuse. Am J Psychiatry. 152:1995;1059-1064
36. Gunderson JG. The borderline patient's intolerance of aloneness: insecure attachments and therapist availability. Am J Psychiatry. 153:1996;752-758
37. West M, Keller A, Links P, Patrick J. Borderline disorder and attachment pathology. Can J Psychiatry. 38:(suppl 1):1993;S16-S22
38. Siever LJ, Torgersen S, Gunderson JG, Livesley WJ, Kendler KS. The borderline diagnosis III: identifying endophenotypes for genetic studies. Biol Psychiatry. 51:2002;964-968
39. Soloff PH, Kelly TM, Strotmeyer SJ, Malone KM, Mann JJ. Impulsivity, gender, and response to fenfluramine challenge in borderline personality disorder. Psychiatry Res. 119:2003;11-24
40. Leyton M, Okazawa H, Diksic M, et al. Brain regional alpha-[C-11] Methyl-(L)-Tryptophan trapping in impulsive subjects with borderline personality disorder. Am J Psychiatry. 158:2001;775-782
41. New AS, Hazlett EA, Buchsbaum MS, Goodman M, Koenigsberg HW, Iskander L. M-CPP PET and impulsive aggression in borderline personality disorder. Biol Psychiatry. 53:2003;104S
42. De la Fuente JM, Goldman S, Stanus E, et al. Brain glucose metabolism in borderline personality disorder. J Psychiatr Res. 31:1997;531-541
43. Soloff PH, Meltzer CC, Becker C, Greer PJ, Kelly TM, Constantine D. Impulsivity and prefrontal hypometabolism in borderline personality disorder. Psychiatry Res. 123:2003;153-163
44. Juengling FD, Schmahl C, Hesslinger B, et al. Positron emission tomography in female patients with borderline personality disorder. J Psychiatr Res. 37:2003;109-115
45. Soloff PH, Meltzer CC, Greer PJ, Constantine D, Kelly TM. A fenfluramine-activated FDG-PET study of borderline personality disorder. Biol Psychiatry. 47:2000;540-547
46. Lyoo IK, Han MH, Cho DY. A brain MRI study in subjects with borderline personality disorder. J Affect Disord. 50:1998;235-243
47. Tebartz van Elst L, Hesslinger B, Thiel T, et al. Frontolimbic brain abnormalities in patients with borderline personality disorder: a volumetric magnetic resonance imaging study. Biol Psychiatry. 54:2003;163-171
48. van Elst LT, Thiel T, Hesslinger B, et al. Subtle prefrontal neuropathology in a pilot magnetic resonance spectroscopy study in patients with borderline personality disorder. J Neuropsych Clin Neurosci. 13:2002;511-514
49. Schmahl CG, Elzinga BM, Vermetten E, Sanislow C, McGlashan TH, Bremner JD. Neural correlates of memories of abandonment in women with and without borderline personality disorder. Biol Psychiatry. 54:2003;142-151
50. Schmahl CG, Vermetten E, Elzinga BM, Bremner JD. A positron emission tomography study of memories of childhood abuse in borderline personality disorder. Biol Psychiatry. 55:2004;759-765
51. Fanselow MS, Gale GD. The amygdala, fear, and memory. Ann NY Acad Sci. 985:2003;125-134
52. Herpertz SC, Dietrich TM, Wenning B, et al. Evidence of abnormal amygdala functioning in borderline personality disorder: a functional MRI study. Biol Psychiatry. 50:2001;292-298
53. Donegan NH, Sanislow CA, Blumberg HP, et al. Amygdala hyperreactivity in borderline personality disorder: implications for emotional dysregulation. Biol Psychiatry. 54:2003;1284-1293
54. Driessen M, Herrmann J, Stahl K, et al. Magnetic resonance imaging volumes of the hippocampus and the amygdala in women with borderline personality disorder and early traumatization. Arch Gen Psychiatry. 57:2000;1115-1122
55. Schmahl CG, Vermetten E, Elzinga BM, Douglas BJ. Magnetic resonance imaging of hippocampal and amygdala volume in women with childhood abuse and borderline personality disorder. Psychiatry Res. 122:2003;193-198
56. Rinne T, de Kloet ER, Wouters L, Goekoop JG, DeRijk RH, van den Brink W. Hyperresponsiveness of hypothalamic-pituitary-adrenal axis to combined dexamethasone/corticotropin-releasing hormone challenge in female borderline personality disorder subjects with a history of sustained childhood abuse. Biol Psychiatry. 52:2002;1102-1112
57. Skodol AE, Buckley P, Charles E. Is there a characteristic pattern to the treatment history of clinic outpatients with borderline personality? J Nerv Ment Dis. 171:1983;405-410
58. Perry JC, Herman JL, van der Kolk BA, Hoke LA. Psychotherapy and psychological trauma in borderline personality disorder. Psychiatric Annals. 20:1990;33-43
59. Geller JL. In again, out again: preliminary evaluation of a state hospital's worst recidivists. Hosp Comm Psychiatry. 37:1986;386-390
60. Surber RW, Winkler EL, Monteleone M, Havassy BE, Goldfinger SM, Hopkin JT. Characteristics of high users of acute psychiatric inpatient services. Hosp Comm Psychiatry. 38:1987;1112-1114
61. Swigar ME, Astrachan B, Levine MA, Mayfield V, Radovich C. Single and repeated admissions to a mental health center: demographic, clinical and use of service characteristics. Int J Soc Psychiatry. 37:1991;259-266
62. Woogh CM. A cohort through the revolving door. Can J Psychiatry. 31:1986;214-221
63. Tucker L, Bauer SF, Wagner SC, Harlam D. Long-term hospital treatment of borderline patients: a descriptive outcome study. Am J Psychiatry. 144:1987;1443-1448
64. Perry JC, Cooper SH. Psychodynamics, symptoms, and outcome in borderline and antisocial personality disorders and bipolar type II affective disorder. McGlashan TH. The borderline: current empirical research. 1985;21-41 American Psychiatric Press, Washington, DC
65. Rascati JN. Managed care and the discharge dilemma: commentary. Psychiatry J Study Interpersonal Process. 53:1990;124-126
66. Linehan MM, Rizvi SL, Welch SS, Page B. Psychiatric aspects of suicidal behaviour: personality disorders. Hawton K, Van Heeringen K. International handbook of suicide and attempted suicide. 2000;147-178 John Wiley & Sons, Sussex
67. Linehan MM, Armstrong HE, Suarez A, Allmon D, Heard HL. Cognitive-behavioral treatment of chronically parasuicidal borderline patients. Arch Gen Psychiatry. 48:1991;1060-1064
68. Linehan MM, Heard HL, Armstrong HE. Naturalistic follow-up of a behavioral treatment for chronically parasuicidal borderline patients. Arch Gen Psychiatry. 50:1993;971-974
69. Linehan MM, Tutek DA, Heard HL, Armstrong HE. Interpersonal outcome of cognitive behavioral treatment for chronically suicidal borderline patients. Am J Psychiatry. 151:1994;1771-1776
70. Linehan MM, Heard HL. Impact of treatment accessibility on clinical course of parasuicidal patients: in reply to Hoffman RE. Arch Gen Psychiatry. 50:1993;158
71. Linehan MM, Schmidt HI, Dimeff LA, Craft JC, Kanter J, Comtois KA. Dialectical behavior therapy for patients with borderline personality disorder and drug-dependence. Am J Addict. 8:1999;279-292
72. Linehan MM, Dimeff LA, Reynolds SK, et al. Dialectical behavior therapy versus comprehensive validation therapy plus 12-step for the treatment of opioid dependent women meeting criteria for borderline personality disorder. Drug Alcohol Depend. 67:2002;13-26
73. Turner RM. Naturalistic evaluation of dialectical behavior therapy-oriented treatment for borderline personality disorder. Cognit Behav Practice. 7:2000;413-419
74. Koons CR, Robins CJ, Tweed JL, et al. Efficacy of dialectical behavior therapy in women veterans with borderline personality disorder. Behav Ther. 32:2001;371-390
75. Verheul R, van den Bosch LMC, Koeter MWJ, De Ridder MAJ, Stijnen T, van den Brink W. Dialectical behaviour therapy for women with borderline personality disorder: 12-month, randomised clinical trial in the Netherlands. Br J Psychiatry. 182:2003;135-140
76. van den Bosch LM, Verheul R, Schippers GM, van den BW. Dialectical behavior therapy of borderline patients with and without substance use problems: implementation and long-term effects. Addict Behav. 27:2002;911-923
77. Linehan MM, Comtois KA, Brown M, et al. DBT versus nonbehavioral treatment by experts in the community: clinical outcomes. Symposium presentation for the Association for Advancement of Behavior Therapy. University of Washington, Reno NV, 2002.
78. Bateman A, Fonagy P. Effectiveness of partial hospitalization in the treatment of borderline personality disorder: A randomized controlled trial. Am J Psychiatry. 156:1999;1563-1569
79. Bateman A, Fonagy P. Treatment of borderline personality disorder with psychoanalytically oriented partial hospitalization: an 18- month follow-up. Am J Psychiatry. 158:2001;36-42
80. Barley WD, Buie SE, Peterson EW, et al. Development of an inpatient cognitive-behavioral treatment program for borderline personality disorder. J Personal Disord. 7:1993;232-240
81. McCann RAB, Ball EM, Ivanoff A. DBT with an inpatient forensic population: the CMHIP forensic model. Cognit Behav Practice. 7:2000;447-456
82. Stanley B, Ivanoff A, Brodsky BS, Oppenheim S. Comparison of DBT and treatment as usual in suicidal and self-mutilating behavior. Paper presented at the 32nd annual convention of the Association for the Advancement of Behavior Therapy. Washington, DC, November, 1998.
83. Bohus M, Haaf B, Stiglmayr CE, Pohl U, Boehme R, Linehan MM. Evaluation of inpatient dialectical-behavioral therapy for borderline personality disorder: a prospective study. Behav Res Ther. 38:2000;875-887
84. Bohus M, Haaf B, Simms T, et al. Effectiveness of inpatient dialectical behavioral therapy for borderline personality disorder: a controlled trial. Behav Res Ther. 42:2004;487-499
85. Rathus JH, Miller AL. Dialectical behavior therapy adapted for suicidal adolescents. Suicide Life Threat Behav. 32:2002;146-157
86. Clarkin JF, Foelsch PA, Levy KN, Hull JW, Delaney JC, Kernberg OF. The development of a psychodynamic treatment for patients with borderline personality disorder: a preliminary study of behavioral change. J Personal Disord. 15:2001;487-495
87. Linehan MM. Behavioral treatments of suicidal behaviors. definitional obfuscation and treatment outcomes. Ann N Y Acad Sci. 836:1997;302-328
88. Zanarini MC, Frankenburg FR, Hennen J, Silk KR. Mental health service utilization by borderline personality disorder patients and Axis II comparison subjects followed prospectively for 6 years. J Clin Psychiatry. 65:2004;28-36
89. Soloff PH, George A, Swami N, Schulz PM, Ulrich RF, Perel JM. Progress in pharmacotherapy of borderline disorders: a double-blind study of amitriptyline, haloperidol, and placebo. Arch Gen Psychiatry. 43:1986;691-697
90. Cowdry RW, Gardner DL. Pharmacotherapy of borderline personality disorder: alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Arch Gen Psychiatry. 45:1988;111-119
91. Soloff PH, Cornelius JR, George A, Nathan RS, Perel JM, Ulrich RF. Efficacy of phenelzine and haloperidol in borderline personality disorder. Arch Gen Psychiatry. 50:1993;377-385
92. Rinne T, van den Brink W, Wouters L, van Dyck R. SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. Am J Psychiatry. 159:2002;2048-2054
93. Markovitz PJ. Pharmacotherapy of impulsivity, aggression, and related disorders. Hollander E, Stein DJ. Impulsivity and aggression. 1995;263-287 John Wiley & Sons, Chichester, UK
94. Salzman C, Wolfson AN, Schatzberg A, et al. Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol. 15:1995;23-29
95. Goldberg SC, Schulz SC, Schulz PM, Resnick RJ, Hamer RM, Friedel RO. Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo. Arch Gen Psychiatry. 43:1986;680-686
96. Zanarini MC, Frankenburg FR. Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. J Clin Psychiatry. 62:2001;849-854
97. De la Fuente JM, Lotstra F. A trial of carbamazepine in borderline personality disorder. Eur Neuropsychopharmacol. 4:1994;479-486
98. Hollander E, Allen A, Lopez RP, et al. A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. J Clin Psychiatry. 62:2001;199-203
99. Frankenburg FR, Zanarini MC. Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study. J Clin Psychiatry. 63:2002;442-446
100. Zanarini MC, Frankenburg FR. Omega-3 fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study. Am J Psychiatry. 160:2003;167-169
101. Schmahl CG, Bohus M. Symptomorientierte Pharmakotherapie bei Borderline-Persönlichkeitsstörung. Fortschr Neurol Psychiatr. 69:2001;310-321
102. Soloff PH. Psychopharmacology of borderline personality disorder. Psychiatr Clin North Am. 23:2000;169-192
103. Soloff PH, George A, Nathan RS, et al. Amitriptyline versus haloperidol in borderlines: final outcomes and predictors of response. J Clin Psychopharmacol. 9:1989;238-246
104. Frankenburg FR, Zanarini MC. Clozapine treatment of borderline patients: a preliminary study. Compr Psychiatry. 34:1993;402-405
105. Chengappa KNR, Ebeling T, Kang JS, Levine J, Parepally H. Clozapine reduces severe self-mutilation and aggression in psychotic patients with borderline personality disorder. J Clin Psychiatry. 60:1999;477-484
106. Rocca P, Marchiaro L, Cocuzza E, Bogetto F. Treatment of borderline personality disorder with risperidone. J Clin Psychiatry. 63:2002;241-244
107. Schulz SC, Camlin KL, Berry SA, Jesberger JA. Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. Biol Psychiatry. 46:1999;1429-1435
108. Cornelius JR, Soloff PH, George A, Ulrich RF, Perel JM. Haloperidol vs. phenelzine in continuation therapy of borderline disorder. Psychopharmacol Bull. 29:1993;333-337
109. Coccaro EF, Kavoussi RJ. Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. Arch Gen Psychiatry. 54:1997;1081-1088
110. Hollander E, Tracy KA, Swann AC, et al. Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. Neuropsychopharmacology. 28:2003;1186-1197
111. Pinto OC, Akiskal HS. Lamotrigine as a promising approach to borderline personality: an open case series without concurrent DSM-IV major mood disorder. J Affect Disord. 51:1998;333-343
112. Shaffer D, Pfeffer CR, Bernet W, et al. Practice parameter for the assessment and treatment of children and adolescents with suicidal behavior. J Am Acad Child Adolesc Psychiatry. 40:2001;24S-51S
113. Philipsen A, Richter H, Schmahl CG, et al. Clonidine in acute aversive inner tension and self-injurious behavior in female patients with borderline personality disorder. J Clin Psychiatry (in press).
114. Bohus M, Landwehrmeyer B, Stiglmayr CE, Limberger MF, Boehme R, Schmahl CG. Naltrexone in the treatment of dissociative symptoms in patients with borderline personality disorder: an open-label trial. J Clin Psychiatry. 60:1999;598-603
115. Cornelius JR, Soloff PH, Perel JM, Ulrich RF. Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine. Am J Psychiatry. 150:1993;1843-1848
116. Shea MT, Stout R, Gunderson J, et al. Short-term diagnostic stability of schizotypal, borderline, avoidant, and obsessive-compulsive personality disorders. Am J Psychiatry. 159:2002;2036-2041
117. Tohen M, Hennen J, Zarate CM Jr, et al. Two-year syndromal and functional recovery in 219 cases of first-episode major affective disorder with psychotic features. Am J Psychiatry. 157:2000;220-228
118. Coryell W, Endicott J, Maser JD, Mueller T, Lavori P, Keller M. The likelihood of recurrence in bipolar affective disorder: the importance of episode recency. J Affect Disord. 33:1995;201-206
119. Zanarini MC, Frankenburg FR, Hennen J, Silk KR. The longitudinal course of borderline psychopathology: 6-year prospective follow-up of the phenomenology of borderline personality disorder. Am J Psychiatry. 160:2003;274-283
120. Paris J, Zweig-Frank H. A 27-year follow-up of patients with borderline personality disorder. Compr Psychiatry. 42:2001;482-487
121. Stone MH. The fate of borderline patients: successful outcome and psychiatric practice. 1990;Guilford Press, New York
122. McGlashan TH. Prediction of outcome in BPD. McGlashan TH. The borderline: current empirical research. 1985;61-98 American Psychiatric Press, Washington, DC
123. Paris J, Brown R, Nowlis D. Long-term follow-up of borderline patients in a general hospital. Compr Psychiatry. 28:1987;530-535
124. Paris J, Nowlis D, Brown R. Developmental factors in the outcome of borderline personality disorder. Compr Psychiatry. 29:1988;147-150
125. Plakun EM. Prediction of outcome in borderline personality disorder. J Personal Disord. 5:1991;93-101
126. Swenson CR, Torrey WC, Koerner K. Implementing dialectical behavior therapy. Psychiatr Serv. 53:2002;171-178